Document is current
Any future updates will be listed below
-
Authors
Carlsen, Esben Andreas http://orcid.org/0000-0002-5231-4197
Lindholm, Kristian http://orcid.org/0000-0002-6240-4233
Hindsholm, Amalie
Gæde, Mathias
Ladefoged, Claes Nøhr
Loft, Mathias
Johnbeck, Camilla Bardram
Langer, Seppo Wang
Oturai, Peter
Knigge, Ulrich
Kjaer, Andreas http://orcid.org/0000-0002-2706-5547
Andersen, Flemming Littrup
-
Funding
Funding for this research was provided by:
Horizon 2020 (670261, 668532)
Danmarks Grundforskningsfond (126)
Lundbeckfonden
Novo Nordisk Fonden
Innovationsfonden
Kræftens Bekæmpelse
Arvid Nilssons Fond
Neye Foundation
Rigshospitalet
Region Hovedstaden
Sundhedsstyrelsen
John and Birthe Meyer Foundation
Sundhed og Sygdom, Det Frie Forskningsråd
Neuroendocrine Tumor Research Foundation
- License Information
-
More Information
Article History
Received: 18 February 2022
Accepted: 7 May 2022
First Online: 28 May 2022
Declarations
:
: A Danish Patient Safety Authority approval was obtained (31–1521-453) for this retrospective study. Due to the retrospective study design, obtaining informed consent was waived for the included patients. All methods were carried out in accordance with relevant guidelines and regulations.
: A Danish Patient Safety Authority approval was obtained (31–1521-453) and consent was waived.
: Ulrich Knigge and Andreas Kjaer are inventors/holds IPR on a patent application: “PET tracer for imaging of neuroendocrine tumors” (WO 2013029616 A1). No other potential conflicts of interest relevant to this article exist.
